Log in  First Connection? Edition EN | FR

Chikungunya  Archives

 Chikungunya
Chikungunya virus virus-like particle vaccine safety and immunogenicity in adults older than 65 years: a phase 3, randomised, double-blind, placebo-controlled trial

Published on 22/04/2025 |  Original article (Full-text)  | Tindale, Lauren C et al. | The Lancet 2025; 405(10487): 1353-61 4 min.

Adults older than 65 years are at increased risk for atypical presentations of chikungunya disease, as well as for severe outcomes including death. In this phase 3, randomised, double-blind, placebo-controlled, parallel-group trial, adults aged 65 years and older received a single intramuscular dose...